Chemical industry – Page 39
-
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
-
ResearchWaste vegetable oils turned into chemicals for drugs and plastics
Dual catalytic system converts complex carboxylic acids into terminal alkenes
-
BusinessSmall biocides companies face uncertain fate
Cost and complexity of European law hampers innovation and excludes SMEs
-
BusinessCancer immunotherapy spreads rapidly
New approvals and expanded use for checkpoint inhibitor drugs illustrate the power of Nobel-winning science
-
-
RSC£50bn chemistry SME sector under threat from Brexit
Access to skills and funding ‘crucial’ to protect sector’s long-term future
-
OpinionThe projects drug companies wish they’d never started
Failures are common in drug research, but some are bigger than others
-
ResearchRemote controlled self-optimising flow synthesis
Online interface could allow virtual sharing of complex kit, and enable simple improvement of reaction conditions
-
ArticleContinuous manufacturing could revolutionise drug development
Continuous flow manufacturing of pharmaceuticals offer the flexibility to accelerate the drug development process
-
BusinessCleaning up clinical trials
Campaigns to enforce complete and correct reporting of trial data are beginning to take hold
-
BusinessNovartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
OpinionHas Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
-
Business‘No deal’ Brexit guidance fails to reassure UK chemical industry
UK government issues guidance on chemical regulation and patent law if the UK leaves the EU without agreement
-
-
BusinessIndia moves to ban cocktail drugs
Government injunction on 328 fixed dose combinations is strongly opposed by manufacturers
-
-
BusinessLandmark China cancer drug full approval ‘first of a wave’
Chi-Med’s fruquintinib is a result of China’s evolving drug innovation and regulation
-
NewsBitter feuding at Cochrane healthcare audit body paralyses organisation
One member has been expelled from the governing board while another four resign with accusations of pharmaceutical industry bias flying
-
BusinessBuilding resilience to climate threats
As extreme weather events become more frequent, chemical and pharmaceutical producers are taking steps to fend them off in future
-
ResearchGenentech antibiotic quells resistance
Modified arylomycin combines high potency with new mechanism of action